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Table
Characteristics N ¼12
Disease e N (%) Krabbe Disease 3 (25%)
MHC II Deﬁciency 2 (17%)
Metachromatic Leukodystrophy 1 (8%)
Hunter Syndrome 1 (8%)
Diamond-Blackfan Anemia 1 (8%)
Cartilage-Hair Hypoplasia 1 (8%)
Combined Immunodeﬁciency 1 (8%)
HLH 1 (8%)
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Background: The use of 4/6 matched cord blood units in-
creases access to hematopoietic stem cell transplantation
particularly for racial and ethnic minority patients. We con-
ducted an analysis to identify factors that favor longer term
survival in patients transplanted with single 4/6 matched
cord blood (CB) grafts after myeloablative conditioning at a
single center.
Methods: We retrospectively reviewed all consecutive single
CB transplants in patients ages <21 years using a myeloa-
blative regimen from 08/1993-04/2012 at Duke using 4/6
matched (low-res HLA-A and B; high-res DRB1) unrelated
donors. Prognostic factors were assessed in univariate KM
analyses of overall survival (OS), disease free survival (DFS)
and cumulative incidence (CInc) of neutrophil and platelet
engraftment, acute grades III-IV graft-versus-host disease
(GVHD) and chronic GVHD. Cox proportional hazards models
were constructed using backward selection. P-values <0.05
were considered statistically signiﬁcant inmultivariatemodel.
Results: 365 patients (68% Caucasian. 62.5% CMV+) with a
median age of 6.28 years with malignant (MAL, n¼208) and
non-malignant (nMAL, n¼157) diagnoses were identiﬁed
with a median follow-up of 10.9 years (range, 1.4-19.9 years).
Median cell dose was 6.3x10e7/kg overall and was higher in
the nMAL group (8.47) which included younger children. The
CInc of neutrophil engraftment was 77.9%, 80% and 75.2% and
platelet engraftment was 54.2%, 51.2% and 58.2% for the total,
MAL and nMAL cohorts, respectively. Graft failure or autol-
ogous recovery occurred in 24 (6.6%) and 12 (3.3%) patients.
The probability of OS at 1, 5, 10 and 15 years was 57.3%, 47.6%,
46.2% and 46.2% in all patients and did not differ signiﬁcantly
for the MAL and nMAL cohorts. The probability of DFS at 1, 5,
10 and 15 years in the MAL cohort was 47.6%, 42.2%, 41.7%
and 41.7%. The CInc of acute GVHD grades III-IV by 100 days
was 14% and of chronic GVHD was 13.7% at 1 and 18.2% at 2
years. On multivariate analysis, OS in all patients and DFS in
MAL cohort was favorably impacted by recipient CMV sero-
negativity and a cell dose of >2.5x10e7/kg measured on the
pre-cryopreservation graft. In the MAL cohort, DFS was bet-
ter in recipients of a gender mismatched graft and HLA
matching. In the nMAL cohort, a cell dose >6.62x10e7/kg
was associated with higher OS. Engraftment was better in
recipients of higher cell dose grafts and in donor/recipient
pairs matched at HLA-B. Acute GVHD was higher in black
recipients overall, and higher when the donor/recipient pairs
were not matched for race.
Conclusions: 4/6 matched UCBT is an effective treatment for
children with MAL and nMAL diseases leading to long term
survival. Impact of cell dose, race, gender and differential
HLA matching will improve donor selection. These outcomes
are similar to those reported with better matched UCB grafts
and support the use of 4/6 UCBT for patients lacking a closer
matched donor.Osteopetrosis 1 (8%)
Donor Match e N (%) 6/6 5 (42%)
5/6 3 (25%)
4/6 4 (33%)
Acute GVHD - N (%) Grade I 2 (17%)
Grade II 2 (17%)
Grade III-IV 1 (8%)
GVHD Target Organ - N (%) Skin 4 (33%)
GI 2 (17%)99
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PAReduced-intensity conditioning (RIC) regimens have been
shown to decrease transplant-related morbidity and mor-
tality; however, this comes with an increased risk of
graft failure and morbidity/mortality secondary to in-
fections following intense serotherapy. Here we report on a
novel RIC conditioning regimen for chemotherapy naïve
children.
Between 2012 and 2013, 12 consecutive patients (median
age 1 year, range: 0.5-14 years) underwent single unit
umbilical cord blood transplantation (UCBT) at the Chil-
dren’s Hospital of Pittsburgh (Table). Patients received
alemtuzumab (1.2-2.2 mg/kg), hydroxyurea (30 mg/kg/
day), ﬂudarabine (150 mg/m2), melphalan (140 mg/m2),
and thiotepa (200 mg/m2), with tacrolimus and mycophe-
nolate as GVHD prophylaxis. Most patients received an
HLA-mismatched unit. The median cell dose was 8.6 x107
(range: 3.8-11.0 x107) TNC/kg and 2.55 x105 (range 1.55-
6.17 x105) CD34+ cells/kg.
Neutrophil engraftment was rapid, and occurred in all
patients at a median of 15.5 days post-UCBT (range: 12-
31). Platelet engraftment (>50K) occurred at a median of
40.5 days post-UCBT (range 32-63). 11 of 12 patients had
>98% donor whole blood chimerism at ﬁrst measurement,
performed at a median of 30 days post-UCBT. The median
chimerism was 100% in whole blood (range: 89-100%) and
T cell fraction (range 95-100%) at 6 months post-UCBT
(n¼7), and 96% (range: 85-100%) in whole blood and 91%
(range 76-100%) in the T cell fraction at 12 months (n¼5).
In a limited sample of patients, TREC number and TCR Vb
repertoire achieved pre-transplant values by 9 months
post-UCBT (Figure). 5 patients (42%) developed viremia
with CMV (n¼2), adenovirus (n¼1), EBV (n¼2), or HHV-6
(n¼3); however, no patients developed end-organ disease.
The incidence of acute GVHD was low, with 25% of pa-
tients developing grade II-IV acute GVHD, and only one
with grade III acute GVHD. All patients responded to
therapy. None of the 9 patients who are beyond Day
180 post-UCBT have developed extensive chronic GVHD.
5 of the 6 patients evaluable at 1 year post-UCBT are
completely off systemic immunosuppression. All patients
are alive with a median follow-up of 11 months (range 3-
25 months).
In conclusion, this novel RIC regimen allows for rapid
engraftment of donor cells and immune reconstitution with
acceptable rates of viral reactivation and GVHD.
Figure. Panel A shows the median number and range of sjTREC copies/10^5 T cells plotted on the left Y-axis and shown using ﬁlled squares and solid lines. The
median and range of TCR Vb spectrotype complexity score (SCS) is plotted on the right Y-axis and shown using open circles and dashed lines. A normal SCS is equal to
184 (Wu CJ et al., Blood 2000). Panel B shows a representative TCR Vb repertoire pre- and post-UCBT.
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Early onset inﬂammatory bowel disease and other intractable
enteropathies of childhood (IEOC) comprise a heterogenous
range of genetically deﬁned and undeﬁned conditions, asso-
ciated with immune dysregulation. These disorders have an
extremely poor prognosis and are associatedwith poor quality
of life and a high mortality from the complications of parental
nutrition +/- prolonged immunosuppressive therapy. Given
emerging data that many of these patients have an underlying
genetic disorder of immune regulation, we have developed a
UK National Commissioning Group programme of allogeneic
stem cell transplant (SCT) for IEOC. We now report initial data
on this novel indication for SCT.
